Compare IE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IE | AUPH |
|---|---|---|
| Founded | 2020 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2022 | 2014 |
| Metric | IE | AUPH |
|---|---|---|
| Price | $9.25 | $17.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $18.17 | $17.25 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | $3,244,000.00 | ★ $283,055,000.00 |
| Revenue This Year | $44.79 | $17.54 |
| Revenue Next Year | $16.22 | $15.74 |
| P/E Ratio | ★ N/A | $70.20 |
| Revenue Growth | 11.82 | ★ 20.38 |
| 52 Week Low | $8.50 | $7.29 |
| 52 Week High | $21.55 | $19.25 |
| Indicator | IE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 55.23 |
| Support Level | N/A | $14.37 |
| Resistance Level | $15.18 | N/A |
| Average True Range (ATR) | 0.72 | 0.70 |
| MACD | -0.20 | 0.16 |
| Stochastic Oscillator | 2.23 | 38.62 |
Ivanhoe Electric Inc is a United States-based d minerals exploration company with a focus on developing mines from mineral deposits principally located in the United States. The company has four business segments; Santa Cruz Project; critical metals; data processing services; and energy storage. It derives a majority of its revenue from Canada. The Santa Cruz Project and critical metals segments are focused on mineral project exploration and development. The data processing segment provides data analytics, geophysical modeling, and artificial intelligence services for the mineral, oil & gas, and water exploration industries. The energy storage segment develops, manufactures, and installs vanadium flow batteries for grid-scale energy storage.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.